Friday, 14 September - 1:15pm (Lunch and Learn Workshop)
Globally there have been growing concerns around the use of opioid based analgesics which locally in Australia has resulted in the upscheduling of codeine combination analgesics. Alternative analgesics featuring the fixed dose combination [FDC] of paracetamol and ibuprofen in two strengths have become available in Australia. Availability around the world and relevant research data around the new paracetamol and ibuprofen FDCs is discussed including in relation to codeine combination analgesics.
Dr Hartley Atkinson is a registered pharmacist who has a Masters of Pharmaceutical Chemistry with distinction and Doctorate in Pharmacology from Otago University, New Zealand. He has published 23 research papers [including the world leading New England Journal of Medicine] and 2 book chapters. Following a stint at Swiss based Multinational Pharmaceutical giant, Roche, where he held positions as Medical Director and later Sales and Marketing Director, Hartley founded AFT Pharmaceuticals in September 1997 with startup capital of NZ$50,000. Today AFT has operations in Australia, New Zealand, Singapore and Malaysia with licensing and distribution agreement in 124 countries in total around the world. R&D work is centred around analgesia, a revolutionary drug delivery system called NasoSURF and an orphan drug project. AFT Pharmaceuticals listed on the ASX & NZX in December 2015 with the founders maintaining a significant stake. The capital raised is being used to invest in accelerating the R&D portfolio of Key Innovative Products that AFT plans to sell around the world in addition to further expanding the local ANZ business.